Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.